Pyrrolopyrimidines as phosphodiesterase VII inhibitors

US7498334B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Hans-Michael Eggenweiler · Darmstadt, DE
• Michael Wolf · Darmstadt, DE

Key dates

• Filing date: Nov 8, 2002
• Grant date: Mar 3, 2009
• Expiry date: Jul 11, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pyrrolopyrimidine derivatives of the formula Iin which R3, R4, R5, R6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.